New combo therapy aims to shrink Hard-to-Treat cancers
NCT ID NCT05951608
First seen Mar 05, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This early-stage trial tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also seeing if the combination can shrink tumors or slow cancer growth. About 216 adults aged 18-75 with good overall health are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 430022, China
Conditions
Explore the condition pages connected to this study.